Astegolimab, a fully human immunoglobulin G2 monoclonal antibody, which binds with high affinity to ST2 to prevent binding of IL-33, is a potential therapy for COPD. This evidence concerns the gene IL1RL1 and chronic obstructive pulmonary disease.